AMRI to Present Two Posters at AAPS 2016

Monday, November 14, 2016 General News J E 4

ALBANY, N.Y., Nov. 14, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a premier contract services provider to the life sciences industry, will be presenting two posters at the 2016 AAPS Annual Meeting and Exposition, at the Colorado Convention Center in Denver. The posters will showcase data supporting AMRI's innovative approach to solving complex scientific problems that arise in drug development.

On Monday, AMRI's poster on "Artificial Stomach and Duodenum: A Dynamic Dissolution Approach," will presented by Yizheng Cao, scientist, at 9 a.m., Terminal 14.

In addition, Greg Thomas, scientist, SSCI, a division of AMRI, will present "Alcohol-Induced Dose Dumping Studies on Buproprion Hydrochloride Modified Release Tablets," at 12:30 pm, Monday, Nov. 14, on Terminal 33.

"The research we are presenting at AAPS demonstrates AMRI's deep understanding of complex chemistry," stated Christopher Conway, senior vice president of Discovery and Development Services at AMRI. "We are constantly working on innovative ways to solve the problems that arise during drug development and create state-of-the-art methods to help all of our customers get the most robust early stage data on their drug development programs."

AAPS attendees interested in learning more about AMRI's programs can meet with company representatives at Booth 600.

About AMRI

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product, and Fine Chemicals. For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal).

To view the original version on PR Newswire, visit:




You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Biohealth Innovation Inc. and The MITRE Corporatio...
Novartis drug PKC412 (midostaurin) granted FDA Pri...